Chemistry Letters 1997 543

# Synthesis of an Optically Active $\alpha$ -Tetralone: A Key Intermediate to Natural Benanomicinone

Toshio Nishizuka, Sehei Hirosawa, Masaki Tsushima, Shinichi Kondo, and Daishiro Ikeda\* Institute of Microbial Chemistry, M. C. R. F., 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141

(Received February 26, 1997; CL-970140)

An optically active dihydroxy- $\alpha$ -tetralone was synthesized from methyl  $\alpha$ -D-xylopyranoside via dimethyl (2R,3S)-dihydroxyglutarate. This  $\alpha$ -tetralone is a key intermediate to construct the natural benanomicinone.

\_\_\_\_\_

In our synthetic approach toward benanomic in A, we reported the general synthesis of the substituted 5,6-dihydrobenzo[a]naphthacenequinone (1), an analog of benanomic inone,

Benanomicinone

using Diels-Alder reaction of 2 derived from 4 with 2-chloro-5,7-dimethoxynaphthoquinone in a good yield.<sup>2</sup> This strategy promises to provide an optically active 5,6-dihydroxy-5,6-dihydrobenzo[a]naphthacenequinone by the use of 3 instead of 2 (Scheme 1). Introduction of the two chiral centers on C-5 and C-6 positions is the critical step in the synthesis of the natural benanomicinone. We report here the regio- and stereoselective synthesis of the optically active dihydroxy- $\alpha$ -tetralone (5), which is a precursor of 3, from methyl  $\alpha$ -D-xylopyranoside via dimethyl (2R,3S)-dihydroxyglutarate (6).

OME OME OO OR' CO<sub>2</sub>Me 
$$\rightarrow$$
 CO<sub>2</sub>Me  $\rightarrow$  CO

Scheme 1.

The starting methyl 2,3-O-cyclohexylidene- $\alpha$ -D-xylopyranoside (7),<sup>3</sup> derived from methyl  $\alpha$ -D-xylopyranoside by selective acetal exchange reaction with 1,1-dimethoxycyclohexane, was treated with sulfuryl chloride in pyridine and tributylstannane in the presence of AIBN to afford the 4-deoxy glycoside (8). Removal of acetal of 8 with 1 M HCl in dioxane followed by benzylation with benzyl bromide and sodium hydride gave di-O-benzyl ether, which was hydrolyzed with 1 M

HCl at 100 °C and oxidized with PDC to give the dibenzyloxy- $\delta$ -lactone (9).  $[\alpha]_0^{p2}$  +85.0° (c 0.8, CH<sub>2</sub>Cl<sub>2</sub>). Sequential treatment of 9 with p-toluenesulfonic acid in MeOH and PDC in CH<sub>2</sub>Cl<sub>2</sub> followed by PDC-MeOH in DMF provided dimethyl (2R,3S)-2,3-dibenzyloxyglutarate (10).<sup>4</sup>  $[\alpha]_0^{p2}$  +24.5° (c 0.8, CH<sub>2</sub>Cl<sub>2</sub>) (Scheme 2).

a)  $SO_2Cl_2$ , pyridine (50%); b)  $Bu_3SnH$ , AlBN, toluene (99%); c) 1 M HCl, dioxane, r. t. (100%); d) BnBr, NaH, DMF (83%); e) 1 M HCl, dioxane, 100 °C; f) PDC,  $CH_2Cl_2$  (58% in two steps); g) p-TSA, MeOH (83%); h) PDC,  $CH_2Cl_2$  (73%); i) PDC, MeOH, DMF (66%).

#### Scheme 2.

The dual Claisen condensation was employed to yield 5. The dibenzyloxyglutarate 10 was condensed with methyl acetoacetate by Yamaguchi's method<sup>5</sup> to provide an undesired  $\alpha$ -tetralone (11, 20%)<sup>4</sup> along with a 7-epimer (12, 8%)<sup>6</sup> (Scheme 3). The clear observation of NOE between 4-H and 5-H<sub>2</sub> confirmed the structure of 11.

10 
$$a, b$$
  $BnO$   $5$   $4$   $CO_2Me$   $BnO$   $7$   $CO_2Me$   $BnO$   $CO_2Me$   $CO_2Me$ 

a) Methyl acetoacetate, NaH, BuLi, THF; b)  $Ca(OAc)_2$ , MeOH, reflux.

### Scheme 3.

10 
$$\xrightarrow{a}$$
  $\xrightarrow{HO_1...}$   $\xrightarrow{CO_2Me}$   $\xrightarrow{b, c}$   $\xrightarrow{b, c}$   $\xrightarrow{b}$   $\xrightarrow{b}$   $\xrightarrow{b}$   $\xrightarrow{b}$   $\xrightarrow{b}$   $\xrightarrow{cO_2Me}$   $\xrightarrow{b}$   $\xrightarrow{b}$   $\xrightarrow{b}$   $\xrightarrow{c}$   $\xrightarrow{b}$   $\xrightarrow{c}$   $\xrightarrow{c}$ 

a) 1,4-Cyclohexadiene,  $Pd(OH)_2$ , EtOH; b) Methyl acetoacetate, NaH, BuLi, THF; c)  $Ca(OAc)_2$ , MeOH, reflux.

### Scheme 4.

When dimethyl (2R,3S)-2,3-dihydroxyglutarate (6),4  $[\alpha]$ <sup>5</sup> -17.5°  $(c\ 1,\ CHCl_3)$ , derived from **10** by de-O-benzylation with Pd $(OH)_2$  and 1,4-cyclohexadiene in EtOH was treated with

544 Chemistry Letters 1997

methyl acetoacetate in the same manner as 10, the desired  $\alpha$ -tetralone 5,4 [ $\alpha$ ] $_{0}^{25}$  +8.9° (c 1, CHCl<sub>3</sub>), was obtained as a sole product even in 11% yield (Scheme 4). The structure of 5 was fully assigned by NMR experiments. The cross peak between 4-H ( $\delta$  7.16) and C-5 ( $\delta$  72.8) was observed in HMBC spectrum of 5. The coupling constant between 5- and 6-H ( $J_{5,6}$  = 8.9 Hz) revealed that the stereochemistry of 6 has been retained in 5. The regioselectivity of the condensation has been explained in the literature.<sup>6</sup> We have had a key intermediate for the synthesis of benanomicinone in hand.

In order to obtain a large quantity of 5, improvement of the yield of the dual Claisen condensation is under investigation.

## References and Notes

- T. Takeuchi, T. Hara, H. Naganawa, M. Okada, M. Hamada, H. Umezawa, S. Gomi, M. Sezaki, and S. Kondo, *J. Antibiotics*, **41**, 807 (1988).
- S. Hirosawa, T. Nishizuka, S. Kondo, and D. Ikeda, *Chem. Lett.*, **1997**, 305.
- F. H. Bissett, M. E. Evans, and F. W. Parrish, Carbohydr. Res., 5, 184 (1967)
- 4 **10**: FABMS *m/z* 373 (MH+). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.67 (1H, dd, *J*=16.1 and 7.3 Hz, 4-H), 2.74 (1H, dd, *J*= 16.6 and 6.4 Hz, 4-H), 3.59 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 3.76 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 4.15 (1H, d, *J*=3.9 Hz, 2-H), and 4.30 (1H, m, 3-H). **6**: FAB-MS *m/z* 193 (MH+). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.63 (1H, dd, *J*=16.6 and 4.4 Hz, 4-H), 2.75 (1H, dd, *J*=16.1 and 8.3 Hz, 4-H), 3.02 (1H,

d, J=4.4 Hz, 3-OH), 3.09 (1H, d, J=5.9 Hz, 2-OH), 3.72 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 3.85 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 4.15 (1H, broad dd, 2-H), and 4.40 (1H, m, 3-H). 11: FABMS m/z 505 (MH+). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.99 (1H, dd, J=17.1 and 8.3 Hz, 5-H), 3.31 (1H, dd, J=17.1 and 3.9 Hz, 5-H), 3.69 (3H, s, CO<sub>2</sub>-CH<sub>3</sub>), 3.71 (2H, s, CH<sub>2</sub>CO<sub>2</sub>), 3.91 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 4.05 (1H, m, 6-H), 4.15 (1H, d, J=7.8 Hz, 7-H), 6.94 (1H, s, 4-H), and 12.59 (1H, s, hydrogen-bonded 1-OH). 5: FABMS m/z 325 (MH+) and 347 (MNa+). 1H NMR (CDCl<sub>3</sub> and a drop of CD<sub>3</sub>OD)  $\delta$  2.72 (1H, dd, J=17.8 and 11.1 Hz, 7-H), 3.11 (1H, dd, J=17.8 and 4.4 Hz, 7-H), 3.71 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 3.77 (2H, s, CH<sub>2</sub>CO<sub>2</sub>), 3.92 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 4.01 (1H, ddd, J=11.1, 8.9, and 4.4 Hz, 6-H), 4.60 (1H, d, J=8.9 Hz, 5-H), and 7.16 (1H, s, 4-H).  $^{13}C$  NMR (CDCl<sub>3</sub> and a drop of CD<sub>3</sub>OD)  $\delta$  39.8 (CH<sub>2</sub>CO<sub>2</sub>), 44.2 (C-7), 52.3 (ester CH<sub>3</sub> x 2), 70.5 (C-6), 72.8 (C-5), 114.8 (C-8a), 119.7 (C-4), 121.5 (C-2), 141.7 (C-3), 146.4 (C-4a), 160.0 (C-1), 166.6 (CO<sub>2</sub>), 170.8 (CH<sub>2</sub>CO<sub>2</sub>), and 201.8 (C-8).

- M. Yamaguchi, K. Hasebe, H. Higashi. M. Uchida, A. Irie, and T. Minami, J. Org. Chem., 55, 1611 (1990).
- Compound 12 was characterized after 1-*O*-methylation with MeI and Ag<sub>2</sub>O in benzene. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.14 (1H, dd, *J*=18.2 and 3.6 Hz, 5-H), 3.32 (1H, dd, *J*=18.2 and 5.4 Hz, 5-H), 3.64 (2H, ABq, *J*=12 Hz, CH<sub>2</sub>CO<sub>2</sub>), 3.69 (3H, s, CO<sub>2</sub>CH<sub>3</sub>), 3.89 and 3.90 (each 3H, OCH<sub>3</sub>), 4.19 (1H, m, 6-H), 4.26 (1H, d, *J*=2.2 Hz, 7-H), and 6.94 (1H, s, 4-H).